Unravel Biosciences Partners with TMA Precision Health to Advance Drug Treatment for Rett Syndrome into the Clinic

Excerpt from the Press Release:

BOSTON, July 5, 2022 /PRNewswire/ — Unravel Biosciences, Inc. (“Unravel”), a therapeutics company that spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University, seamlessly bridges target discovery with clinical efficacy to advance drugs for complex diseases, today announced a partnership with TMA Precision Health (“TMA”), a Startup Health platform for rare diseases, aimed at identifying rare Rett Syndrome patients for inclusion in Unravel’s first-in-human reformulated drug trial. Unravel will leverage TMA’s unique access to rare disease patients to pre-enrich its clinical trial enrollment and accelerate their work for this extremely rare condition that currently has no cure.

Rett Syndrome is a rare neurodevelopmental disorder that occurs primarily in girls and impacts the whole body, including cognitive and fine motor functions. The disorder is equally present worldwide and affects one in every 10,000 live births, making it challenging to find patients to participate in clinical trials. TMA’s database of patients from global sources makes it easier to locate the right patients and advance promising therapies through clinical development.

Unravel’s proprietary BioNAV™ platform combines network-based computational prediction, patient transcriptomic information, and a first-in-class unbiased Xenopus platform to decode, model, and develop new therapeutics for complex diseases. Unravel’s approach developed RVL001, a proprietary oral liquid formulation that improves clinically-relevant metrics and will be evaluated in rapid, data-rich clinical trials to de-risk uncovered drug targets.

Click the button below to read the entire Press Release:

Continue Reading The Press Release